Cardioprotective Effect of &bgr;-Adrenoceptor Blockade in Patients With Breast Cancer Undergoing Chemotherapy: Follow-Up Study of Heart Failure

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Circulation: Heart Failure

• Publication date

  2013-02-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCHEARTFAILURE.112.000055PMID 23425978
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Cardioprotective interventions for cancer patients receiving anthracyclines.

  2011cited by this paper
• Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.

  2011cited by this paper
• Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?

  2010cited by this paper
• Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation.

  2010cited by this paper
• Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy.

  2010cited by this paper
• Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab.

  2009cited by this paper
• Cardioprotective interventions for cancer patients receiving anthracyclines.

  2008cited by this paper
• Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.

  2007cited by this paper
• Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury.

  2006cited by this paper
• Herceptin and the heart--a molecular modifier of cardiac failure.

  2006cited by this paper
• Protective effects of carvedilol against anthracycline-induced cardiomyopathy.

  2006cited by this paper
• Cardiotoxicity induced by chemotherapy and antibody therapy.

  2006cited by this paper
• Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio

  2005cited by this paper
• Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.

  2005cited by this paper
• Clinical cardiac tolerability of trastuzumab.

  2004cited by this paper
• Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation

  2004influential reference
• Health profiles in 5836 long‐term cancer survivors

  2003cited by this paper
• ErbB2 is essential in the prevention of dilated cardiomyopathy

  2002cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques

  2001cited by this paper
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper
• A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.

  1987cited by this paper

• Cancer Therapy‐Induced Cardiotoxicity: A Narrative Review

  2026cites this paper
• Advance at a glance: contributions to cardio-oncology

  2025cites this paper
• Cardioprotection in patients with anthracycline-treated breast cancer: final analysis from the 2 × 2 randomized, placebo-controlled, double-blind SAFE trial

  2025cites this paper
• Cardioprotective drugs and heart failure/cardiomyopathy incidence in chemotherapy-treated cancer survivors of breast cancer and non-Hodgkin lymphoma: a retrospective cohort study in England

  2025cites this paper
• Factors Associated With the Recovery of Left Ventricular Ejection Fraction in Patients With Anthracycline-Induced Left Ventricular Dysfunction

  2025cites this paper
• Primary prevention of left ventricular dysfunction and heart failure in cancer patients undergoing chemotherapeutic treatment: a systematic review

  2025cites this paper
• The importance of the Autostrain RV technique in the treatment of right ventricular myocardial alterations in patients with breast cancer receiving chemotherapy

  2025cites this paper
• Trastuzumab Cardiotoxicity: Mechanism and Management.

  2025cites this paper
• Interventions for prevention and treatment of trastuzumab-induced cardiotoxicity: an umbrella review of systematic reviews and meta-analyses

  2024cites this paper
• The intersection of heart failure and cancer in women: a review

  2024cites this paper
• Natural Products for Preventing and Managing Anthracycline-Induced Cardiotoxicity: A Comprehensive Review

  2024cites this paper
• Diagnostic and Therapeutic Approaches for Heart Failure in Long-Term Survivors of Childhood Cancer

  2024cites this paper
• Neurobiology of cancer: Adrenergic signaling and drug repurposing.

  2024cites this paper
• β-blockers and statins: exploring the potential off-label applications in breast, colorectal, prostate, and lung cancers

  2024cites this paper
• The use of quadrotherapy of chronic heart failure in cancer patients (case series)

  2023cites this paper
• Traditional risk factors and cancer-related factors associated with cardiovascular disease risk in head and neck cancer patients

  2023cites this paper
• Guarding the Heart: How SGLT-2 Inhibitors Protect Against Chemotherapy-induced Cardiotoxicity: SGLT-2 Inhibitors and Chemotherapy-induced Cardiotoxicity.

  2023cites this paper
• Addressing Cardiovascular Risk Across the Arc of a Woman’s Life: Sex-Specific Prevention and Treatment

  2023cites this paper
• Breast Cancer and the Cardiovascular Disease: A Narrative Review

  2022cites this paper
• Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies

  2022cites this paper
• PREVENTION AND MANAGEMENT OF ANTHRACYCLINE INDUCED CARDIOTOXICITY: A REVIEW

  2022cites this paper
• Global Longitudinal Strain for the Early Detection of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis.

  2022cites this paper
• Prevention of Anthracycline-Induced Cardiotoxicity: The Good and Bad of Current and Alternative Therapies

  2022cites this paper
• Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection

  2022cites this paper
• Time to switch angiotensin-converting enzyme inhibitors/angiotensin receptor blockers to sacubitril/valsartan in patients with cancer therapy-related cardiac dysfunction

  2022cites this paper
• Cancer and cardiovascular disease: can understanding the mechanisms of cardiovascular injury guide us to optimise care in cancer survivors?

  2022influential citation
• Diretriz de Miocardites da Sociedade Brasileira de Cardiologia – 2022

  2022cites this paper
• Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy

  2021cites this paper
• Physiological And Pathological Roles Of Protein Kinase A In The Heart.

  2021cites this paper
• Clozapine-Associated Myocarditis

  2021cites this paper
• Cardiovascular complications in patients with cancer: focus on anthracycline-induced cardiotoxicity

  2021cites this paper
• Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications

  2021cites this paper
• Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin

  2021cites this paper
• How to early identify anthracycline-induced cardiotoxicity and reduce its clinical impact in everyday practice.

  2021cites this paper
• Recomendaciones para el manejo de la cardiotoxicidad relacionada con el tratamiento del cáncer. Primera parte

  2021cites this paper
• Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer

  2021cites this paper
• Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial

  2021cites this paper
• Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative.

  2020cites this paper
• In Vivo Evaluation of Carvedilol Cardiac Protection Against Trastuzumab Cardiotoxicity

  2020cites this paper
• Cardiotoxicity of Anthracyclines

  2020cites this paper
• Antioxidant Approach as a Cardioprotective Strategy in Chemotherapy-Induced Cardiotoxicity

  2020cites this paper
• Srčno popuščanje in onkološko zdravljenje

  2020cites this paper
• A case series about the favorable effects of sacubitril/valsartan on anthracycline cardiomyopathy

  2020cites this paper
• Hydrophilic vs. Lipophilic Statins in Diabetic Patients　― Comparison of Long-Term Outcomes After Acute Myocardial Infarction ―

  2020cites this paper
• Kardioonkologija - novi izazov u kliničkoj praksi

  2020cites this paper
• Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors

  2019cites this paper
• Cardiovascular Complications in Cancer Therapy

  2019cites this paper
• Cardiotoxicidad por trastuzumab en pacientes con cáncer de mama. Serie de casos

  2019influential citation
• Cardiac Toxicity of HER-2 Targeted Regimens

  2019cites this paper
• Role of Cardioprotective Agents on Chemotherapy-induced Heart Failure: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.

  2019cites this paper
• Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors

  2019cites this paper
• Beta-blockers for the primary prevention of anthracycline-induced cardiotoxicity: a meta-analysis of randomized controlled trials

  2019cites this paper
• Treatment of chemotherapy-associated cardiomyopathy

  2019cites this paper
• Cardioprotective effect of renin–angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity

  2019cites this paper
• Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: Insights from in vitro, in vivo, and clinical studies in breast cancer patients

  2019cites this paper
• Assessment of Carvedilol Therapy in Prevention of Heart Failure in HER2 Positive Breast Cancer Patients Receiving Trastuzumab

  2019cites this paper
• Effects of physical exercise on outcomes of cardiac (dys)function in women with breast cancer undergoing anthracycline or trastuzumab treatment: study protocol for a systematic review

  2019cites this paper
• Cardiooncology. Basic principles of prevention and treatment of cardiotoxicity in cancer patients

  2019cites this paper
• Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician

  2019cites this paper
• Oncologic therapies associated with cardiac toxicities: how to minimize the risks

  2019cites this paper
• Evolution of echocardiography in subclinical detection of cancer therapy–related cardiac dysfunction

  2018cites this paper
• Beta-Blockers for Primary Prevention of Anthracycline Cardiotoxicity: Not Quite Ready for Prime Time.

  2018cites this paper
• The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients

  2018cites this paper
• Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Part I

  2018influential citation
• Cardiac toxicity of HER2-targeted regimens

  2018cites this paper
• Cardiovascular Disease and Breast Cancer: Where These Entities Intersect A Scientific Statement From the American Heart Association

  2018cites this paper
• Cardioprotection in the Modern Era of Cancer Chemotherapy

  2018cites this paper
• Heart Failure and Left Ventricular Dysfunction

  2018cites this paper
• Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective

  2018cites this paper
• Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.

  2018cites this paper
• The breast cancer patient in the cardioncology unit.

  2018cites this paper
• Prevention and Clinical Management of Cardiovascular Damage Induced by Anticancer Drugs: Need for Early Biomarkers and Cardio- and Vasculoprotection in Personalized Therapy

  2018cites this paper
• Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial.

  2018cites this paper
• Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction.

  2018cites this paper
• Impaired Cardiorespiratory Fitness Following Thoracic Radiotherapy

  2018cites this paper
• Cardiac Function Assessed by Magnetic Resonance Imaging and Circulating Biomarkers during Adjuvant Breast Cancer Therapy: Effect of Concomitant Neurohormonal Blockade

  2018cites this paper
• Left atrial volume in patients with HER2‐positive breast cancer: One step further to predict trastuzumab‐related cardiotoxicity

  2018cites this paper
• Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer

  2018cites this paper
• Update on pathophysiology and preventive strategies of anthracycline‐induced cardiotoxicity

  2018cites this paper
• Mechanism and Prevention of Cardiomyopathy Due to Chemotherapy

  2018cites this paper
• Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients

  2018cites this paper
• SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab

  2017cites this paper
• From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview

  2017cites this paper
• Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts

  2017cites this paper
• Cardiomyopathic Toxicity From Chemotherapy: Is There an Opportunity for Preemptive Intervention?

  2017cites this paper
• Anthracyclines induce early changes in left ventricular systolic and diastolic function: A single centre study

  2017cites this paper
• Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

  2017cites this paper
• Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies

  2017cites this paper
• High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury

  2017cites this paper
• Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?

  2017cites this paper
• Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations.

  2017cites this paper
• Documento di consenso ANMCO/AICO/AIOM: Snodi clinico-gestionali in ambito cardioncologico

  2017cites this paper
• Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention

  2017cites this paper
• Galician consensus on management of cardiotoxicity in breast cancer: risk factors, prevention, and early intervention

  2017cites this paper
• Cardiac safety of systemic therapy in breast cancer patients with high risk of atherosclerosis complications.

  2017cites this paper
• Management of Heart Failure in Cancer Patients and Cancer Survivors.

  2017cites this paper
• Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer

  2017cites this paper
• Cardio-oncology.

  2017cites this paper
• The Role of Echocardiography in the Detection of Chemotherapy-Induced Cardiotoxicities

  2017cites this paper
• Oncology Drug Therapy: Cardiotoxicity and the Discipline of Cardio-oncology

  2017cites this paper